Takeda Pharmaceutical Co Ltd (TKPYY.PK)

TKPYY.PK on OTC Markets Group

23.04USD
10:51am EDT
Price Change (% chg)

$-0.25 (-1.07%)
Prev Close
$23.29
Open
$23.11
Day's High
$23.18
Day's Low
$23.04
Volume
11,732
Avg. Vol
31,989
52-wk High
$25.09
52-wk Low
$21.64

TKPYY.PK

Chart for TKPYY.PK

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer... (more)
No analyst recommendations are available for TKPYY.PK.

Overall

No Ratios Available.

Financials

  TKPYY.PK Industry Sector
P/E (TTM): -- 35.68 36.12
EPS (TTM): -- -- --
ROI: -- 18.88 18.15
ROE: -- 19.60 18.97
Search Stocks

UPDATE 1-Drug maker Orion's Q2 profit rises on Bayer, Takeda payments

* Result boosted by one-off payments from Bayer and Takeda

29 Jul 2014

Europe approves Takeda drug for ulcerative colitis, Crohn's disease

TOKYO - The European Commission has approved the sale of Takeda Pharmaceutical Co Ltd's Entyvio drug to treat patients with ulcerative colitis and Crohn's disease, Japan's biggest drugmaker said on Wednesday.

27 May 2014

Europe approves Takeda drug for ulcerative colitis, Crohn's disease

TOKYO, May 28 - The European Commission has approved the sale of Takeda Pharmaceutical Co Ltd's Entyvio drug to treat patients with ulcerative colitis and Crohn's disease, Japan's biggest drugmaker said on Wednesday.

27 May 2014

U.S. FDA approves Takeda drug for colitis and Crohn's

May 20 - U.S. health regulators on Tuesday approved a drug from Japan's Takeda Pharmaceutical Co Ltd to treat the chronic debilitating inflammatory diseases ulcerative colitis and Crohn's disease.

20 May 2014

Takeda not interested in synergy or tax-driven M&A - CFO

TOKYO, May 16 - Takeda Pharmaceutical Co Ltd , Japan's biggest drug company, has no interest in acquisitions driven by tax benefits or synergies, its chief financial officer said, dismissing the forces behind Pfizer Inc's $106 billion offer for AstraZeneca PLC.

16 May 2014

Nikkei gains on Yellen comments; Nintendo hit by wider-than-expected loss

* Nintendo tumbles to lowest since June 2013 * Toyota, Takeda to report earnings later in the day * Chinese trade data eyed By Ayai Tomisawa TOKYO, May 8 - Japan's Nikkei share average rose on Thursday, recovering from a three-week low hit the previous day after comments by the U.S. Federal Reserve chief helped investor sentiment, but Nintendo slid after posting a wider-than-expected loss. Nintendo Co fell 5.6 percent to 10,070 yen, its lowest since June 2013, afte

07 May 2014

Update-Moody's affirms Takeda's Aa3 rating: outlook stable

For the full text of this story please click the following link:

09 Apr 2014

Japan drugmaker Takeda to fight $6 billion damages awarded by U.S. jury

SAN FRANCISCO/TOKYO - Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a jury in the United States in a case that accused Japan's largest drugmaker of concealing cancer risks associated with its Actos diabetes drug.

08 Apr 2014

UPDATE 4-Japan drugmaker Takeda to fight $6 bln damages awarded by U.S. jury

* Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly

08 Apr 2014

Japan drugmaker Takeda to fight $6 billion damages imposed by U.S. jury

SAN FRANCISCO/TOKYO - Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging that Japan's largest drugmaker had concealed cancer risks associated with its Actos diabetes drug.

08 Apr 2014

Earnings vs. Estimates

No consensus analysis data available.

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks